Lexaria Bioscience (LEXX) Depreciation & Amortization (CF) (2010 - 2026)
Lexaria Bioscience's (LEXX) quarterly Depreciation & Amortization (CF) came in at $35967.0 in Q1 2026, up 1479.58% year-on-year from $2277.0 in Q1 2025, and up 201.4% quarter-over-quarter from -$35472.0 in Q2 2025.
Lexaria Bioscience (LEXX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Lexaria Bioscience has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $35967.0 for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $35967.0, up 1479.58% year-over-year; the trailing twelve-month figure through Feb 2026 was $495.0 (up 105.36% YoY), and the FY2023 annual result was $145397.0, up 41.55% from the prior year.
- Depreciation & Amortization (CF) came in at $35967.0 for Q1 2026 at Lexaria Bioscience, up from -$35472.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $70928.0 in Q3 2023 to a low of -$59783.0 in Q3 2024.
- The 5-year median for Depreciation & Amortization (CF) is $24730.0 (2022), against an average of $17076.8.
- Across the five-year window, Depreciation & Amortization (CF) tumbled 335.32% in 2025 and soared 1479.58% in 2026, its largest moves.
- Lexaria Bioscience's Depreciation & Amortization (CF) stood at $24730.0 in 2022, then gained by 16.37% to $28778.0 in 2023, then advanced by 15.35% to $33195.0 in 2024, then slumped by 206.86% to -$35472.0 in 2025, then jumped by 201.4% to $35967.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $35967.0 (Q1 2026), -$35472.0 (Q2 2025), and $2277.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 429,663.65 |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 | 35,967.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 35,967.00 |
| Feb 28, 2026 | 35,967.00 |
| May 31, 2025 | -35,472.00 |
| May 31, 2025 | -35,472.00 |
| Feb 28, 2025 | 2,277.00 |
| Feb 28, 2025 | 2,277.00 |
| Nov 30, 2024 | 33,195.00 |
| Nov 30, 2024 | 33,195.00 |
| Aug 31, 2024 | -59,783.00 |
| Aug 31, 2024 | -59,783.00 |
| May 31, 2024 | 15,074.00 |
| May 31, 2024 | 15,074.00 |
| Feb 29, 2024 | 15,931.00 |
| Feb 29, 2024 | 15,931.00 |
| Nov 30, 2023 | 28,778.00 |
| Nov 30, 2023 | 28,778.00 |
| Aug 31, 2023 | 70,928.00 |
| Aug 31, 2023 | 70,928.00 |
| May 31, 2023 | 25,010.00 |
| May 31, 2023 | 25,010.00 |